Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

GST-Hsp90 N(9-236) Citations (7)

Originally described in: Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release.
Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, Fujita N, Tsuruo T, Sessa WC Circ Res. 2002 May 3. 90(8):866-73.
PubMed Journal

Articles Citing GST-Hsp90 N(9-236)

Articles
REV-ERBalpha influences the stability and nuclear localization of the glucocorticoid receptor. Okabe T, Chavan R, Fonseca Costa SS, Brenna A, Ripperger JA, Albrecht U. J Cell Sci. 2016 Nov 1;129(21):4143-4154. Epub 2016 Sep 29. PubMed
Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation. Goode KM, Petrov DP, Vickman RE, Crist SA, Pascuzzi PE, Ratliff TL, Davisson VJ, Hazbun TR. Biochim Biophys Acta. 2017 Aug;1861(8):1992-2006. doi: 10.1016/j.bbagen.2017.05.006. Epub 2017 May 8. PubMed
HSP90 Interacts with the Fibronectin N-terminal Domains and Increases Matrix Formation. Chakraborty A, Boel NM, Edkins AL. Cells. 2020 Jan 22;9(2). pii: cells9020272. doi: 10.3390/cells9020272. PubMed
Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization. Bhatia S, Spanier L, Bickel D, Dienstbier N, Woloschin V, Vogt M, Pols H, Lungerich B, Reiners J, Aghaallaei N, Diedrich D, Frieg B, Schliehe-Diecks J, Bopp B, Lang F, Gopalswamy M, Loschwitz J, Bajohgli B, Skokowa J, Borkhardt A, Hauer J, Hansen FK, Smits SHJ, Jose J, Gohlke H, Kurz T. ACS Cent Sci. 2022 May 25;8(5):636-655. doi: 10.1021/acscentsci.2c00013. Epub 2022 Apr 27. PubMed
Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy. Pan X, Mao TY, Mai YW, Liang CC, Huang WH, Rao Y, Huang ZS, Huang SL. Molecules. 2022 Aug 29;27(17):5561. doi: 10.3390/molecules27175561. PubMed
Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment. Donahue K, Xie H, Li M, Gao A, Ma M, Wang Y, Tipton R, Semanik N, Primeau T, Li S, Li L, Tang W, Xu W. J Biol Chem. 2022 Dec;298(12):102700. doi: 10.1016/j.jbc.2022.102700. Epub 2022 Nov 14. PubMed
Extracellular Hsp90 Binds to and Aligns Collagen-1 to Enhance Breast Cancer Cell Invasiveness. Singh P, Ramanathan V, Zhang Y, Georgakoudi I, Jay DG. Cancers (Basel). 2023 Oct 31;15(21):5237. doi: 10.3390/cancers15215237. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.